Details of the transaction, which is expected to close in the third quarter of 2022, were not disclosed. Also, the deal is not subject to a financing condition or shareholder vote.

Primarily sold under the brand name Cytoplast, Osteogenics offers bone grafting products for periodontal and oral and maxillofacial surgical procedures.